Cardiac sarcoidosis and giant cell myocarditis after COVID-19 infection

Patients infected with SARS-CoV-2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1-8 months after mild COVID-19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID-19 infection might suggest that COVID-19 could be a trigger for granulomatous myocarditis.

Automated summary

This study reports on four cases of cardiac involvement in patients who had mild COVID-19 and later developed symptomatic cardiac sarcoidosis or giant cell myocarditis 1-8 months after infection. All patients showed gradual improvement with immunosuppressive therapy. The temporal association suggests that COVID-19 could potentially trigger granulomatous myocarditis.